Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 1/20 | 0.75 |
| ▸ | TTR | P02766 | 1/20 | 0.75 |
| ▸ | JUN | P05412 | 1/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.75 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.75 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.69 |
| ▸ | MMP1 | P03956 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-O-Methyl-Alpha-Methyldopamine SCHEMBL28514447 | 1.00 | FOS (0.75) | FOSTTRJUNNR3C1HSD17B1 | |
| 3-O-Methyl-Alpha-Methyldopamine SCHEMBL9434236 | 1.00 | FOS (0.75) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL28002729 | 0.86 | ALOX15 (0.75) | FOSTTRJUNNR3C1HSD17B1 | |
| Dihydroguaiaretic Acid SCHEMBL9087980 | 0.86 | FOS (1.00) | FOSTTRJUNNR3C1HSD17B1 | |
| Mesodihydroguaiaretic Acid SCHEMBL974725 | 0.86 | FOS (1.00) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL11571527 | 0.86 | FOS (0.80) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL10509993 | 0.85 | FOS (0.68) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL19337385 | 0.84 | FOS (0.77) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL14532804 | 0.84 | FOS (0.77) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL2564908 | 0.84 | LDHA (0.59) | ALOX15ALOX12TAAR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2021030571-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-18 | — | — | WO | claimed |
| US-12590077-B2 | Short-acting monoamine releasers | Solvonics Therapeutics Ireland Holdings Limited (IE) | 2026-03-31 | — | — | US | disclosed |
| EP-4611738-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Lykos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250134855-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-05-01 | — | — | US | disclosed |
| US-20250134856-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-05-01 | — | — | US | disclosed |
| US-20250127756-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-04-24 | — | — | US | disclosed |
| US-20250127757-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | MAPS PUBLIC BENEFIT CORPORATION | 2025-04-24 | — | — | US | disclosed |
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2025-03-27 | — | — | US | disclosed |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. | 2024-10-10 | — | — | US | disclosed |
| US-20230129723-A1 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | EMPATHBIO, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023056472-A1 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | ATAI Life Sciences AG (DE) | 2023-04-06 | — | — | WO | disclosed |
| US-20230097530-A1 | ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOF | EMPATHBIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230000885-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4013403-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | University of Maryland, Baltimore (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021030571-A1 | METHODS OF TREATING PSYCHOLOGICAL AND BRAIN DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-02-18 | — | — | WO | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-1994000432-A1 | ANORECTIC EPINEPHRINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100990-A1 | 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE | DBH, TSPO, DDO | FOS 3431/4885TTR 3829/4885JUN 3572/4885 |
| US-20250127756-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | FOS 4195/4885TTR 855/4885JUN 4788/4885 |
| US-12590077-B2 | Short-acting monoamine releasers | SLC6A2, NPY2R, SLC6A3 | FOS 4253/4885TTR 3508/4885JUN 3872/4885 |
| US-20250127757-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | FOS 4195/4885TTR 855/4885JUN 4788/4885 |
| US-20250134856-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | FOS 4195/4885TTR 855/4885JUN 4788/4885 |
| US-20250134855-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | SLC6A3, SLC6A2, SLC18A1 | FOS 4195/4885TTR 855/4885JUN 4788/4885 |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | HTR6, HTR4, CNR1 | FOS 1948/4885TTR 919/4885JUN 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.